1 – 10 of 29
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer
(
- Contribution to journal › Scientific review
- 2022
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2022 Update
(
- Contribution to journal › Scientific review
-
Mark
Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
(
- Contribution to journal › Article
- 2021
-
Mark
Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma
(
- Contribution to journal › Article
-
Mark
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium
(
- Contribution to journal › Article
-
Mark
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis : What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature
(
- Contribution to journal › Scientific review
-
Mark
Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
(
- Contribution to journal › Article